The HbA1c test has been proposed for screening and diagnosis of diabetes and pre-diabetes, but it has several limitations as a stand-alone screening test.

GlycoMark has received the maximum allowable amount under the Qualifying Therapeutic Discovery Project (QTDP), part of the Patient Protection and Affordable Care Act of 2010.

GlycoMark president Eric Button said that along with proper medical care and self-management, early detection of diabetes and pre-diabetes is the best way to stave off the life-threatening complications of diabetes.

“There was an extremely competitive approval process for this grant, and we are very pleased to receive these monies for our diabetes research program into early detection,” Button said.

“Results from recent studies indicate that the combined use of HbA1c and 1,5-anhydroglucitol provides more sensitive and specific screening tool for identifying high-risk individuals with diabetes and this grant will assist us in the research and development of an important diagnostic tool to help in the prevention and treatment of a life-threatening disease.”